AI Article Synopsis
- The study evaluated Niaspan, a new niacin formulation, for treating primary hyperlipidemia, focusing on its efficacy, safety, and side effects like flushing and liver toxicity.
- The research involved 122 patients in a 12-week trial, comparing Niaspan at doses of 1000 mg/day and 2000 mg/day to a placebo.
- Results showed that Niaspan significantly reduced low-density lipoprotein cholesterol and triglycerides while increasing high-density lipoprotein cholesterol, and while flushing was common, it was generally manageable for patients.
Article Abstract
BACKGROUND: The present study was designed to determine the efficacy and safety of Niaspan (Kos Pharmaceuticals, Inc, Hollywood, FL), a new controlled-release formulation of niacin, in the treatment of primary hyperlipidemia, the occurrence and severity of flushing events, and potential adverse effects, particularly hepatotoxicity. METHODS AND RESULTS: The study was conducted as a multicenter, randomized, double-blind, placebo-controlled, parallel comparison of Niaspan in doses of 1000 mg/day and 2000 mg/day, administered once a day at bedtime. One hundred twenty-two patients with low-density lipoprotein cholesterol levels >4.14 mM/L (160 mg/dL) with dietary intervention and high-density lipoprotein cholesterol
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/107424849600100302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!